A new post-grant review at the Patent Trial and Appeal Board could be one to watch for companies operating in the dental implant and broader medical-device space. On August 11, 2026, Straumann USA, LLC filed PGR2026-00070, asking the PTAB to review a recently issued patent.

A new post-grant review at the Patent Trial and Appeal Board could be worth close attention for companies operating in the dental implant and medical device space. In PGR2026-00070, filed on August 11, 2026, the proceeding is captioned Straumann USA, LLC, signaling a challenge to a recently issued patent associated with one of the best-known names in dental technology.

At this stage, the docket entry identifies the matter by party name and PTAB number, but practitioners will want to watch for the petition and related filings to clarify the specific patent claims at issue, the identity of the petitioner, and the precise invalidity theories being advanced.

A new post-grant review at the Patent Trial and Appeal Board is worth watching for practitioners tracking early-life patent challenges and the evolving use of PTAB proceedings against recently issued patents. In PGR2026-00064, titled ShoreShade LLC, the petition was filed on July 1, 2026. The proceeding is now on the radar for patent owners, petitioners, and IP counsel evaluating how aggressively to use post-grant review in high-stakes disputes.

At this stage, the docket caption identifies ShoreShade LLC as the patent owner in the PTAB proceeding.

A new post-grant review, PGR2026-00062, was filed at the Patent Trial and Appeal Board on June 25, 2026, putting an America Ugreen Limited patent directly in the PTAB spotlight.

A new post-grant review proceeding at the Patent Trial and Appeal Board could be worth watching for companies and counsel operating in competitive consumer product and health-tech markets. In PGR2026-00051, titled Hyper Ice, Inc., a petitioner has asked the PTAB to review the validity of a recently issued patent associated with Hyper Ice, Inc. The petition was filed on May 26, 2026.

At this early stage, the PTAB docket signals the opening of a post-grant challenge, but practitioners should note that post-grant review itself already says a great deal about the patent at issue.

In a short but useful procedural order, the Patent Trial and Appeal Board granted the patent owner’s unopposed motion to withdraw existing lead counsel and substitute new lead counsel in PGR2025-00086. The order applies 37 C.F.R. § 42.10, the PTAB rule governing counsel recognition and changes in representation, and reflects the Board’s routine but important emphasis on continuity of representation.

Although the ruling does not break new doctrinal ground, it is a practical reminder that PTAB counsel changes are not automatic.

The Patent Trial and Appeal Board’s docket entry in Entegris, Inc., PGR2026-00037, marks the start of a post-grant review proceeding that practitioners should watch closely. Although a newly filed PTAB matter does not yet provide a final merits ruling, the case is significant because post-grant review remains one of the most powerful mechanisms for attacking recently issued patents on a wide range of grounds, including patent eligibility, written description, enablement, indefiniteness, and novelty or obviousness.

Based on the filing posture, the key issue is not yet who ultimately wins, but what the PTAB will permit the challenger to litigate and how aggressively it will examine the patent under the broader PGR framework.